The DOI matches its OpenAlex record; 8 of the 8 references it cites were found in a registry or an index.
The Inhalation of Drugs: Advantages and Problems
Abstract
Inhalation is a very old method of drug delivery, and in the 20th century it became a mainstay of respiratory care, known as aerosol therapy. Use of inhaled epinephrine for relief of asthma was reported as early as 1929, in England. An early version of a dry powder inhaler (DPI) was the Aerohalor, used to administer penicillin dust to treat respiratory infections. In the 1950s, the Wright nebulizer was the precursor of the modern hand-held jet-venturi nebulizer. In 1956, the first metered-dose inhaler (MDI) was approved for clinical use, followed by the SpinHaler DPI for cromolyn sodium in 1971. The scientific basis for aerosol therapy developed relatively late, following the 1974 Sugarloaf Conference on the scientific basis of respiratory therapy. Early data on the drug-delivery efficiency of the common aerosol delivery devices (MDI, DPI, and nebulizer) showed lung deposition of approximately 10-15% of the total, nominal dose. Despite problems with low lung deposition with all of the early devices, evidence accumulated that supported the advantages of the inhalation route over other drug-administration routes. Inhaled drugs are localized to the target organ, which generally allows for a lower dose than is necessary with systemic delivery (oral or injection), and thus fewer and less severe adverse effects. The 3 types of aerosol device (MDI, DPI, and nebulizer) can be clinically equivalent. It may be necessary to increase the number of MDI puffs to achieve results equivalent to the larger nominal dose from a nebulizer. Design and lung-deposition improvement of MDIs, DPIs, and nebulizers are exemplified by the new hydrofluoroalkane-propelled MDI formulation of beclomethasone, the metered-dose liquid-spray Respimat, and the DPI system of the Spiros. Differences among aerosol delivery devices create challenges to patient use and caregiver instruction. Potential improvements in aerosol delivery include better standardization of function and patient use, greater reliability, and reduction of drug loss.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Leach, C., Davidson, P., & Boudreau, R. (1998) · European Respiratory Journal · doi:10.1183/09031936.98.12061346 · Cited by 430
Evolution of dry powder inhaler design, formulation, and performance
NEWMAN, S. P., & BUSSE, W. W. (2002) · Respiratory Medicine · doi:10.1053/rmed.2001.1276 · Cited by 340
The science of nebulised drug delivery
O'Callaghan, C., & Barry, P. W. (1997) · Thorax · doi:10.1136/thx.52.2008.s31 · Cited by 293
Dry Powder Aerosols I: A New Powder Inhalation Device
Bell, J. H., Hartley, P. S., & Cox, J. S. G. (1971) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600601028 · Cited by 202
Design Principles of Liquid Nebulization Devices Currently in Use
Rau, J. L. (2002) · Respiratory Care · doi:10.1177/002013240204701103 · Cited by 105
Self-citationKleerup, E. C., Tashkin, D. P., Cline, A. C., & Ekholm, B. P. (1996) · CHEST Journal · doi:10.1378/chest.109.3.702 · Cited by 63
Brain, J. D. (1980) · American Review of Respiratory Disease · doi:10.1164/arrd.1980.122.5p2.17 · Cited by 59
Metered-dose inhalers and CFCs: what respiratory physicians need to know
Partridge, M. R. (1994) · Respiratory Medicine · doi:10.1016/s0954-6111(05)80060-5 · Cited by 35
Cited by
Aldawood, F. K., Andar, A., & Desai, S. (2021) · Polymers · doi:10.3390/polym13162815 · Cited by 499
Dry Powder Inhaler Formulation
Telko, M. J., & Hickey, A. J. (2005) · Respiratory Care · doi:10.4187/respcare.05501209 · Cited by 498
Medication adherence issues in patients treated for COPD
Restrepo, R. (2008) · International Journal of Chronic Obstructive Pulmonary Disease · doi:10.2147/copd.s3036 · Cited by 407
The History of Therapeutic Aerosols: A Chronological Review
Stein, S. W., & Thiel, C. G. (2017) · Journal of Aerosol Medicine and Pulmonary Drug Delivery · doi:10.1089/jamp.2016.1297 · Cited by 309
Metadata
- Authors
- Rau, J. L.
- Venue
- Respiratory Care
- Publisher
- American Association for Respiratory Care
- Published
- 2005-03-01
- Volume
- 50
- Issue
- 3
- Pages
- 367-382
- ISSN
- 0020-1324 (ISSN-L)
- OpenAlex
- W2127518718
- Cited by
- 279
- References
- 8
- FWCI
- 6.66
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Inhalation of Drugs: Advantages and Problems. https://app.cochat.ai/papers/10.4187/respcare.05500367
- The paper
- Rau, J. L. (2005). The Inhalation of Drugs: Advantages and Problems. Respiratory Care. https://doi.org/10.4187/respcare.05500367
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.